Eligibility
peripheral artery bypass, HIV antibody positive, gastrointestinal stromal tumor, basal cell carcinoma or cervical carcinoma, primary malignant tumor, recurrent/
ADVERSE REACTIONS, BRAIN METASTASIS, CARCINOMATOUS MENINGITIS, MYOCARDIAL INFARCTION, GASTROINTESTINAL STROMAL TUMOR, UNSTABLE ANGINA PECTORIS, SYMPTOMATIC CONGESTIVE HEART FAILURE, SPINAL CORD COMPRESSION, CEREBROVASCULAR ACCIDENT, GIST, ONCOLOGY, DISEASES
Participants were eligible for inclusion if they had recurrent/ metastatic gastrointestinal stromal tumor confirmed by histopathological examination, were 18 years of age or older, have measurable lesions in accordance with RECIST 1.1, and failed the first-line treatment of imatinib or cannot tolerate the adverse reactions, cannot afford the expensive medical expenses of sunitinib and regorafenib or are unwilling to accept their side effects, had an Eastern Cooperative Oncology Group performance status of 0 or 1, have an estimated survival of more than 3 months, and informed consent and signed a written consent. What’s more, the patients have good compliance, and could voluntary follow-up, treatment, laboratory examination, and other research steps as planned.Exclusion criteria included having resectable localized or metastatic GIST, AST and/ or ALT > 2.5 × ULN, or serum total bilirubin >1.5 × ULN, the absolute count of neutrophil (ANC) was less than 1.5 × 109/L, or platelet <75 × 109/L, or HB <90 g/L, Cr >1.5 × ULN, finding the second primary malignant tumor in the past 5 years, except for skin basal cell carcinoma or cervical carcinoma in situ, finding brain metastasis, spinal cord compression, carcinomatous meningitis, or diseases of brain or pia mater detected by CT or MRI during screening stage, or having any of the following diseases within 12 months before enrollment: myocardial infarction, severe/ unstable angina pectoris, coronary/ peripheral artery bypass grafting, symptomatic congestive heart failure or cerebrovascular accident, being serum HIV antibody positive, participating in other clinical trials at present, being pregnant or nursing, or other reasons may be deemed unsuitable for study participation by the investigator.